Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M181,239Revenue $M48,851Net Margin (%)15.9Altman Z-Score2.3
Enterprise Value $M199,791EPS $1.2Operating Margin %25.1Piotroski F-Score6
P/E(ttm)22.1Beneish M-Score-2.7Pre-tax Margin (%)20.0Higher ROA y-yN
Price/Book2.710-y EBITDA Growth Rate %2.3Quick Ratio1.3Cash flow > EarningsY
Price/Sales3.95-y EBITDA Growth Rate %4.2Current Ratio1.6Lower Leverage y-yY
Price/Free Cash Flow13.3y-y EBITDA Growth Rate %-17.4ROA % (ttm)5.6Higher Current Ratio y-yN
Dividend Yield %3.9PEG5.3ROE % (ttm)13.3Less Shares Outstanding y-yY
Payout Ratio %83.0Shares Outstanding M6,173ROIC % (ttm)17.0Gross Margin Increase y-yY

Gurus Latest Trades with PFE

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
PFEDavid Tepper 2015-12-31 Buy 1.55%$31.33 - $35.45
($33.17)
$ 29.36-11%New holding2,412,250
PFEDodge & Cox 2015-12-31 Reduce-1.36%$31.33 - $35.45
($33.17)
$ 29.36-11%Reduce -95.04%2,243,178
PFENWQ Managers 2015-12-31 Reduce-1.16%$31.33 - $35.45
($33.17)
$ 29.36-11%Reduce -54.84%1,967,718
PFEKahn Brothers 2015-12-31 Reduce-0.59%$31.33 - $35.45
($33.17)
$ 29.36-11%Reduce -6.05%1,569,873
PFEFirst Eagle Investment 2015-12-31 Reduce-0.47%$31.33 - $35.45
($33.17)
$ 29.36-11%Reduce -97.77%135,661
PFET Rowe Price Equity Income Fund 2015-12-31 Add0.28%$31.33 - $35.45
($33.18)
$ 29.36-12%Add 15.28%14,525,000
PFEVanguard Health Care Fund 2015-12-31 Reduce-0.25%$31.33 - $35.45
($33.17)
$ 29.36-11%Reduce -29.31%8,872,226
PFECharles Brandes 2015-12-31 Reduce-0.1%$31.33 - $35.45
($33.17)
$ 29.36-11%Reduce -3.82%5,639,537
PFEPrem Watsa 2015-12-31 Reduce-0.07%$31.33 - $35.45
($33.17)
$ 29.36-11%Reduce -10.64%210,000
PFEJohn Keeley 2015-12-31 Reduce-0.04%$31.33 - $35.45
($33.17)
$ 29.36-11%Reduce -38.66%77,749
PFEKen Fisher 2015-12-31 Add0.03%$31.33 - $35.45
($33.18)
$ 29.36-12%Add 1.28%32,334,417
PFEDavid Dreman 2015-12-31 Sold Out -0.02%$31.33 - $35.45
($33.17)
$ 29.36-11%Sold Out0
PFEJames Barrow 2015-12-31 Reduce-0.02%$31.33 - $35.45
($33.17)
$ 29.36-11%Reduce -0.76%53,862,996
PFERichard Pzena 2015-12-31 Add$31.33 - $35.45
($33.17)
$ 29.36-11%Add 0.08%2,161,593
PFEMario Gabelli 2015-12-31 Reduce$31.33 - $35.45
($33.17)
$ 29.36-11%Reduce -3.16%706,956
PFELeon Cooperman 2015-09-30 Buy 3.06%$30.82 - $36.15
($33.8)
$ 29.36-13%New holding4,830,595
PFEKahn Brothers 2015-09-30 Reduce-0.59%$30.82 - $36.15
($33.8)
$ 29.36-13%Reduce -5.85%1,671,039
PFEVanguard Health Care Fund 2015-09-30 Reduce-0.46%$30.82 - $36.15
($33.8)
$ 29.36-13%Reduce -35.29%12,550,992
PFEFirst Eagle Investment 2015-09-30 Add0.14%$30.82 - $36.15
($33.8)
$ 29.36-13%Add 41.13%6,090,294
PFECharles Brandes 2015-09-30 Reduce-0.08%$30.82 - $36.15
($33.8)
$ 29.36-13%Reduce -3.16%5,863,701
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

PFE is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


PFE: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
CANGIALOSI LORETTA VSr. Vice President, Controller 2015-07-30Sell24,704$35.65-17.64view
OLSON LAURIE JExecutive Vice President 2015-06-11Sell26,000$34.39-14.63view
HILL CHARLES HExecutive Vice President 2015-05-29Sell42,870$34.92-15.92view
SUSMAN SALLYExecutive Vice President 2015-03-12Sell46,179$34-13.65view
READ IAN CChairman & CEO 2015-03-05Sell67,500$34.62-15.19view
Dolsten MikaelPresident R&D 2015-03-05Sell58,298$34.46-14.8view
CANGIALOSI LORETTA VSr. Vice President, Controller 2015-02-13Sell104,000$34.73-15.46view
MADDALUNA ANTHONY JExecutive Vice President 2015-02-12Sell9,000$34.85-15.75view
DAMELIO FRANK AExecutive Vice President 2015-02-11Sell80,200$34.23-14.23view
DAMELIO FRANK AExecutive Vice President 2015-02-11Sell14,800$34.3-14.4view

Quarterly/Annual Reports about PFE:

    News about PFE:

    Articles On GuruFocus.com
    Kahn Brothers Sells Part of Stake in Pfizer in 4th Quarter Feb 09 2016 
    Is Apple the Next Altria? Feb 02 2016 
    UnitedHealth Likely to Build on Growth in the Health Care Sector Jan 05 2016 
    Third Avenue Management's Annual Report Dec 29 2015 
    5 Guru Picks in Volatile Biotech Industry Dec 23 2015 
    Jim Simons' Top Holdings Include VeriSign, Chipotle Dec 15 2015 
    A Fed Rate Hike: What Investment Options Await You Dec 15 2015 
    Cooperman's Big Bets Include Alphabet, Pfizer Dec 06 2015 
    Leon Cooperman Adds Google Holdings and Buys Pfizer Nov 23 2015 
    What's Lee Ainslie's Angle to Buy Into a Pharmaceutical Stalwart Yielding 3%? Nov 19 2015 

    More From Other Websites
    Highlights from Billionaire Jim Simons’ Renaissance Technologies’ 13F: Apple, Pfizer & More Feb 12 2016
    Loeb's Allergan Stake Grows by 50% Feb 12 2016
    Don't bail on biotech: Pro Feb 12 2016
    What Does Pfizer’s 2016 Guidance Look Like? Feb 12 2016
    [$$] 3 Stock Picks From Only U.S. Fund That Rose in '08 Feb 12 2016
    Kahn Brothers’ Top Stock Picks for Early 2016; Citigroup Inc. (C) Leading the Pack Feb 11 2016
    [$$] J&J May See $4 Cash-Flow Cut From Remicade Copy Feb 11 2016
    Superbug review says more vaccines needed to reduce antibiotic use Feb 11 2016
    Superbug review says more vaccines needed to reduce antibiotic use Feb 11 2016
    1:43 am Pfizer receives FDA committee vote to approve investigational biosimilar infliximab Feb 11 2016
    Pfizer's Biosimilar of Remicade Recommended for Approval Feb 10 2016
    Relypsa: This Biotech Just Released Stunning Data Feb 10 2016
    Why Pfizer (PFE) Stock Is Rising Today Feb 10 2016
    'I would not want to be a cancer patient in England' says Pfizer boss Feb 10 2016
    3 Value Stocks Ready to Outperform Feb 10 2016
    Panel Recommends FDA Approval of Remicade Knockoff Feb 10 2016
    Short Sellers Increase Bets in Major Pharma Feb 10 2016
    5 Safe, Strong Stocks to Add to Your Portfolio in Uncertain Times Feb 10 2016
    AbbVie, Maker of World's No. 1 Drug, Bets on Synthetic Biology Startup Feb 10 2016
    Panel Recommends FDA Approval of Remicade Knockoff Feb 10 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    Daniel Seens
    ReplyDaniel Seens - 1 year ago
    PFE is trading at the low end of our short-term valuation range ($29-$36) and significantly below our Fair Value estimate of $42.41.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK